GSK: starts phase III study of bronchiolitis vaccine
(CercleFinance.com) - British biopharmaceutical firm GlaxoSmithKline said on Monday that it was starting Phase III trials with a candidate vaccine for maternal immunisation against respiratory syncytial virus (RSV).
This virus is a leading cause of respiratory infections such as bronchiolitis and viral pneumonia in young children, with an estimated 33 million cases in children of below five years old every year.
The virus is also responisble for the hospitalisations of over 1.4 million babies under six months of age.
A maternal vaccination would protect them from birth, GSK said.
Data has showed that the candidate vaccine was well-tolerated and boosted the pre-existing immunity in women who are not pregnant. The first data in pregnant women is expected to be presented in 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.